ID: ALA5176251

Max Phase: Preclinical

Molecular Formula: C21H16Cl2N4O

Molecular Weight: 411.29

Associated Items:

Representations

Canonical SMILES:  Cc1nn(-c2ccc(Cl)cc2Cl)c(C)c1C(=O)Nc1ccc2ccccc2n1

Standard InChI:  InChI=1S/C21H16Cl2N4O/c1-12-20(13(2)27(26-12)18-9-8-15(22)11-16(18)23)21(28)25-19-10-7-14-5-3-4-6-17(14)24-19/h3-11H,1-2H3,(H,24,25,28)

Standard InChI Key:  TZDHOUMEORFGTE-UHFFFAOYSA-N

Associated Targets(Human)

Protein Wnt-3a 90 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 411.29Molecular Weight (Monoisotopic): 410.0701AlogP: 5.60#Rotatable Bonds: 3
Polar Surface Area: 59.81Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 2.36CX LogP: 5.44CX LogD: 5.44
Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.48Np Likeness Score: -2.05

References

1. Ai Y, Sakamuru S, Imler G, Xia M, Xue F..  (2022)  Improving the solubility and antileukemia activity of Wnt/β-catenin signaling inhibitors by disrupting molecular planarity.,  69  [PMID:35777269] [10.1016/j.bmc.2022.116890]

Source